U.S. License Holder:
Coherus
Date of License:
November-02-2018
Last Update:
Nov-15-2024
FDA-Approved Indications
UDENYCA (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to
Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia:
Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
U.S. Patent Litigations
